Respected diagnostics industry expert will help lead efforts to capitalize on market opportunity for Cologuard
MADISON, Wis., Nov. 8, 2016 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the appointment of Jeff Elliott as chief financial officer. Mr. Elliott, a former senior research analyst at Robert W. Baird & Co., joined Exact Sciences as vice president, business development and strategy, in June 2016 and will begin his new role effective immediately.
"Demand for Cologuard is accelerating and an enormous market opportunity lies ahead to achieve our mission of eradicating colon cancer," said Kevin Conroy, Exact Sciences' chairman and CEO. "Jeff's unique understanding of financial strategy and depth of knowledge in the diagnostics sector will help us efficiently capitalize on this opportunity."
Mr. Elliott's experience includes nearly nine years at Baird, most recently as the senior research analyst who covered diagnostics and life science tools companies. Previously in his career, Mr. Elliott worked in various positions at Walgreens and Cap Gemini Ernst & Young. He earned a Bachelor of Science in Business Administration from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the University of Chicago Booth School of Business. Mr. Elliott is a CFA charterholder.
Mr. Elliott will report to Mr. Conroy and continue serving as a member of the executive management team.
John Bakewell is retiring from the CFO role at Exact Sciences after more than 25 years in leadership roles with various health care companies. He will focus on board of director assignments. "We want to thank John for his service to Exact Sciences and dedication to advancing our mission," said Mr. Conroy. "John's efforts during the past year helped to maintain our financial strength and position Exact Sciences for long-term growth."
A high-resolution photo of Mr. Elliott is available here.
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society's (2014) colorectal cancer screening guidelines. Stool DNA is included in the combined screening guidelines of the American Cancer Society/U.S. Multi-Society Task Force/American College of Radiology (2008), the American College of Gastroenterology guidelines (2009) and the National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciencesor find Exact Sciences on Facebook.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the willingness of health insurance companies and other payors to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of any healthcare reforms, including the Affordable Care Act, or changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
CONTACT: JP Fielder, email@example.com, 608 210 5220
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/exact-sciences-appoints-jeff-elliott-chief-financial-officer-300359348.html
SOURCE EXACT SCIENCES CORP
Click Here for a complete listing of Exact Sciences Corporation press releases.